The Form 4 filing, an SEC report of insider stock trades, was filed on November 18, 2026. The trades took place November 16–17. Terrance P. Coyne serves as executive vice president and chief financial officer of Royalty Pharma (RPRX).
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-16 |
| Date of Latest Transaction | 2026-11-17 |
| Buy/Sell | sell |
| Transaction Count | 5 |
| Shares Transacted | 257,122 |
| Price | $68.81 |
| Total Transaction Value | $17,693,642.13 |
| Insider | |
| Ticker Symbol | RPRX |
| Company | Royalty Pharma plc |
| Insider Name | Coyne Terrance P. |
| Insider Title | EVP & CFO |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 0 |
| Position Size Change | 100.00% |
| Filing | |
| Filing Date | 2026-11-18 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a set of five share sales, reported with SEC transaction code S. All five transactions were reported for the same insider in one filing.
What was the average price of the transaction?
The average sale price was $68.81 per share, rounded to cents. This average covers the five transactions. Prices for each separate sale are not available in the transaction details.
How did this transaction affect the insider's holdings?
He sold 257,122 shares, or 100.00% of the shares in the reported balance before the sales. He reported zero shares in that balance afterward. The available details do not show whether he held shares in other accounts or through other forms of ownership.
What's the total transaction value?
The five sales had a total value of $17,693,642.13, rounded to cents. This amount covers all five transactions together.
Are there any special circumstances around this transaction?
The transaction information includes a Rule 10b5-1 trading-plan reference. These plans set trading instructions in advance. Footnote text and plan terms are not available here, so it is unclear whether the reference covers all five sales. The plan's start date and trading schedule are also unknown.
For research purposes only; not investment advice.